HK1096399A1 - P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same p- - Google Patents

P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same p-

Info

Publication number
HK1096399A1
HK1096399A1 HK07103870.2A HK07103870A HK1096399A1 HK 1096399 A1 HK1096399 A1 HK 1096399A1 HK 07103870 A HK07103870 A HK 07103870A HK 1096399 A1 HK1096399 A1 HK 1096399A1
Authority
HK
Hong Kong
Prior art keywords
same
pharmaceutical composition
preparing
glycoprotein inhibitor
anticancer agent
Prior art date
Application number
HK07103870.2A
Other languages
English (en)
Inventor
Keuk Chan Bang
Mi Young Cha
Young Gil Ahn
Young Jin Ham
Maeng Sup Kim
Gwan Sun Lee
Original Assignee
Hanmi Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of HK1096399A1 publication Critical patent/HK1096399A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • General Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
HK07103870.2A 2003-10-07 2007-04-13 P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same p- HK1096399A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030069582A KR100557093B1 (ko) 2003-10-07 2003-10-07 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
PCT/KR2004/002550 WO2005033097A1 (en) 2003-10-07 2004-10-06 P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
HK1096399A1 true HK1096399A1 (en) 2007-06-01

Family

ID=36500896

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07103870.2A HK1096399A1 (en) 2003-10-07 2007-04-13 P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same p-

Country Status (23)

Country Link
US (1) US7625926B2 (xx)
EP (1) EP1678162B1 (xx)
JP (1) JP4481992B2 (xx)
KR (1) KR100557093B1 (xx)
CN (1) CN1863795B (xx)
AT (1) ATE466008T1 (xx)
AU (1) AU2004277475B2 (xx)
BR (1) BRPI0415053B8 (xx)
CA (1) CA2541301C (xx)
DE (1) DE602004026903D1 (xx)
DK (1) DK1678162T3 (xx)
ES (1) ES2342290T3 (xx)
HK (1) HK1096399A1 (xx)
IL (1) IL174665A (xx)
MX (1) MXPA06003803A (xx)
NO (1) NO336127B1 (xx)
NZ (1) NZ546257A (xx)
PL (1) PL1678162T3 (xx)
PT (1) PT1678162E (xx)
RU (1) RU2317985C1 (xx)
SI (1) SI1678162T1 (xx)
WO (1) WO2005033097A1 (xx)
ZA (1) ZA200603538B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700773D0 (en) * 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8822497B2 (en) 2007-03-01 2014-09-02 Novartis Ag PIM kinase inhibitors and methods of their use
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
CN102203079B (zh) 2008-09-02 2014-12-10 诺华股份有限公司 作为激酶抑制剂的吡啶甲酰胺衍生物
KR101466245B1 (ko) 2010-01-15 2014-12-01 한미사이언스 주식회사 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
WO2013175388A1 (en) 2012-05-21 2013-11-28 Novartis Ag Novel ring-substituted n-pyridinyl amides as kinase inhibitors
KR101986683B1 (ko) 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
CN103804352B (zh) * 2014-01-23 2017-06-13 中国药科大学 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用
KR20150135110A (ko) * 2014-05-23 2015-12-02 한미정밀화학주식회사 p-당단백질의 저해제 및 p-당단백질의 기질 약물을 포함하는 약제학적 조성물
CN104327046B (zh) * 2014-10-14 2017-11-17 中国药科大学 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用
JO3737B1 (ar) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان
TWI752750B (zh) 2015-09-30 2022-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
WO2019200290A1 (en) * 2018-04-13 2019-10-17 Athenex Therapeutics Limited Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of angiosarcoma
CN113631161A (zh) * 2018-12-14 2021-11-09 慧源香港创新有限公司 用于治疗癌症的口服施用的多西他赛和P-gp抑制剂的治疗组合
CA3122699A1 (en) * 2018-12-14 2020-06-18 Athenex HK Innovative Limited Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancer
US20220135548A1 (en) 2019-02-14 2022-05-05 Teva Pharmaceuticals International Gmbh Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5- dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide and of its mesylate salt
WO2020230037A1 (en) * 2019-05-13 2020-11-19 Dr. Reddy's Laboratories Limited Alternate process for the preparation of encequidar
WO2021044350A1 (en) * 2019-09-04 2021-03-11 Dr. Reddy’S Laboratories Limited Solid forms of encequidar mesylate and processes thereof
US20230278990A1 (en) 2020-07-10 2023-09-07 Teva Czech Industries S.R.O Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide mesylate salt
AU2021358074A1 (en) 2020-10-07 2023-04-27 Athenex, Inc. Acetamido-phenyltetrazole derivatives and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930702292A (ko) * 1990-11-06 1993-09-08 알렌 제이. 스피겔 종양 치료 활성을 증대시키기 위한 퀴나졸린 유도체
JP3223193B2 (ja) 1991-08-09 2001-10-29 株式会社日清製粉グループ本社 インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質
DE69310367T2 (de) 1992-07-10 1997-08-14 Glaxo Lab Sa Anilide-derivate
GB9717576D0 (en) * 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
AU3408901A (en) * 2000-02-15 2001-08-27 Teijin Ltd Cancer remedy comprising anthranilic acid derivative as active ingredient
CN100349888C (zh) 2002-05-14 2007-11-21 埃克森诺瓦有限公司 药物化合物
KR100580743B1 (ko) 2003-10-08 2006-05-15 한미약품 주식회사 다약제 내성 저해 활성을 갖는 신규한 크로몬 유도체 또는이의 약제학적으로 허용가능한 염 및 이들의 제조 방법

Also Published As

Publication number Publication date
RU2006114427A (ru) 2007-11-20
NZ546257A (en) 2009-09-25
CA2541301C (en) 2010-02-02
CA2541301A1 (en) 2005-04-14
NO336127B1 (no) 2015-05-18
JP4481992B2 (ja) 2010-06-16
EP1678162A1 (en) 2006-07-12
BRPI0415053B8 (pt) 2021-05-25
WO2005033097A1 (en) 2005-04-14
SI1678162T1 (sl) 2010-07-30
EP1678162A4 (en) 2008-07-02
IL174665A0 (en) 2006-08-20
JP2007507493A (ja) 2007-03-29
US20070072900A1 (en) 2007-03-29
IL174665A (en) 2012-10-31
KR20050033734A (ko) 2005-04-13
EP1678162B1 (en) 2010-04-28
DE602004026903D1 (de) 2010-06-10
US7625926B2 (en) 2009-12-01
ZA200603538B (en) 2007-09-26
RU2317985C1 (ru) 2008-02-27
ATE466008T1 (de) 2010-05-15
MXPA06003803A (es) 2006-07-03
ES2342290T3 (es) 2010-07-05
DK1678162T3 (da) 2010-08-02
NO20062019L (no) 2006-07-06
BRPI0415053B1 (pt) 2019-12-31
AU2004277475A1 (en) 2005-04-14
AU2004277475B2 (en) 2007-08-09
CN1863795B (zh) 2011-05-18
PL1678162T3 (pl) 2010-09-30
KR100557093B1 (ko) 2006-03-03
PT1678162E (pt) 2010-05-19
BRPI0415053A (pt) 2006-11-28
CN1863795A (zh) 2006-11-15

Similar Documents

Publication Publication Date Title
HK1096399A1 (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same p-
MXPA05009985A (es) Ligandos de receptores de canabinoides.
EP1714961A4 (en) INDAZOL COMPOUND AND THEIR PHARMACEUTICAL USE
UA96449C2 (xx) Стабільні препарати лаквінімоду$стабильные препараты лаквинимода
GB9914486D0 (en) Medicaments
ATE450533T1 (de) Carboxamidderivate
RS52904A (xx) Farmaceutske smeše oralno aktivnih derivata taksana koje imaju povećanu bioraspoloživost
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
WO2005117895A8 (en) Compositions comprising meloxicam
TNSN06220A1 (en) Benzimidazole derivatives
EP1839662A4 (en) ANTITUMOR AGENT
MXPA03010761A (es) Combinaciones farmaceuticas.
GB0109122D0 (en) Novel compounds
AU2003239389A1 (en) Opioid receptor antagonists
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
WO2005013935A3 (en) Composition for releasing a weak base for an extended period of time
WO2003089449A3 (fr) Composes aminoalkylsteroles avec activite anti-tumeur et neuroprotective
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
TW200510370A (en) Urea derivatives
TW200626567A (en) Benzoxazine and quinoxaline derivatives and uses
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments